Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Aix, S.P.; Talbot, D.; Govindan, R.; Dols, M.C.; Postmus, P.E.; Lewanski, C.; Bennouna, J.; Fischer, J.R.; Juan-Vidal, O.; Stewart, D.J.; Ardizzoni, A.; Bhore, R.; Wolfsteiner, M.; Reck, M.; Ong, T.J.; Morgensztern, D.

doi:doi:10.2217/fon-2019-0796

Persistent URL of this record https://hdl.handle.net/1887/3184835

View statistics

In Collections

This item can be found in the following collections:

Medicine / Leiden University Medical Centre (LUMC)

Aix, S.P.; Talbot, D.; Govindan, R.; Dols, M.C.; Postmus, P.E.; Lewanski, C.; ... ; Morgensztern, D. (2020)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer

Article / Letter to editor

Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel +/- durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively....Show moreAim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel +/- durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.Show less

durvalumab

EORTC QLQ-C30

EQ-5D-5L

lung cancer symptom scale

nab-paclitaxel

non-small cell lung cancer

quality of life